Literature DB >> 12970018

Predicting mortality in patients with sarcoidosis awaiting lung transplantation.

Andrew F Shorr1, Darcy B Davies, Steven D Nathan.   

Abstract

OBJECTIVES: To identify factors associated with mortality in patients with sarcoidosis listed for lung transplantation, and to create a model for predicting intermediate-term mortality in these individuals.
DESIGN: Retrospective cohort study of patients with sarcoidosis listed for lung transplant in the United States between 1995 and 2000. After identifying important risk factors for death, we developed a mortality prediction model based on an inception cohort of 75% of the subjects. The remaining 25% of the individuals served as a validation cohort for determining the validity of the model. SETTING AND PATIENTS: All patients with sarcoidosis in the United States irrespective of referral center listed for lung transplantation between 1995 and 2000.
MEASUREMENTS AND MAIN RESULTS: Adequate follow-up data were available for 405 patients, and 111 patients (27.4%) died while awaiting lung transplantation. Neither patient age nor gender correlated with mortality. Survivors and nonsurvivors did not differ based on the results of spirometric testing. African Americans faced a significantly increased risk of death, which persisted after controlling for other confounders (odds ratio, 2.5). The amount of supplemental oxygen used and the mean pulmonary artery pressure were the only other variables predictive of mortality. The mean (+/- SD) pulmonary artery pressure in those who survived was 31.7 +/- 11.5 mm Hg, compared to 41.4 +/- 14.4 mm Hg in nonsurvivors (p < 0.01). Survivors required 2.2 +/- 2.0 L/min of oxygen vs 2.9 +/- 1.7 L/min in those who died awaiting transplant (p < 0.01). Differences in pulmonary artery pressures did not reflect differences in cardiac status, as the pulmonary capillary wedge pressure and the cardiac index were similar in survivors and nonsurvivors. The final mortality prediction model included three variables: race, amount of supplemental oxygen needed, and mean pulmonary artery pressure. Based on the validation cohort, the concordance of the model for death within 2 years of listing was 0.61 (95% confidence interval, 0.47 to 0.76), indicating only moderate explanatory power.
CONCLUSIONS: Race, pulmonary hypertension, and oxygen use are important factors indicative of mortality in this population. Specific guidelines for determining time of referral for transplantation in advanced sarcoidosis should be developed. Recommendations extrapolated from data for other types of interstitial lung disease may not be applicable in sarcoidosis. The independent effect of race on outcome is troubling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970018

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  36 in total

1.  The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease.

Authors:  Harry Karmouty-Quintana; Hongyan Zhong; Luis Acero; Tingting Weng; Ernestina Melicoff; James D West; Anna Hemnes; Almut Grenz; Holger K Eltzschig; Timothy S Blackwell; Yang Xia; Richard A Johnston; Dewan Zeng; Luiz Belardinelli; Michael R Blackburn
Journal:  FASEB J       Date:  2012-03-13       Impact factor: 5.191

2.  Renal transplantation in patients with sarcoidosis: a French multicenter study.

Authors:  Jessie Aouizerate; Marie Matignon; Nassim Kamar; Eric Thervet; Christine Randoux; Bruno Moulin; Loic Raffray; Matthias Buchler; Emmanuel Villar; Mathieu Mahevas; Dominique Desvaux; Karine Dahan; Carine Diet; Vincent Audard; Philippe Lang; Philippe Grimbert
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

Review 3.  Morbidity and mortality in sarcoidosis.

Authors:  Alicia K Gerke
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

4.  Expression profiling elucidates a molecular gene signature for pulmonary hypertension in sarcoidosis.

Authors:  Sunit Singla; Tong Zhou; Kamran Javaid; Taimur Abbasi; Nancy Casanova; Wei Zhang; Shwu-Fan Ma; Michael S Wade; Imre Noth; Nadera J Sweiss; Joe G N Garcia; Roberto F Machado
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 5.  Significance of main pulmonary artery dilation on imaging studies.

Authors:  Timothy E Raymond; Joseph E Khabbaza; Ruchi Yadav; Adriano R Tonelli
Journal:  Ann Am Thorac Soc       Date:  2014-12

6.  Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors.

Authors:  Aggeliki Rapti; Vasileios Kouranos; Elias Gialafos; Konstantina Aggeli; John Moyssakis; Anastasios Kallianos; Charalampos Kostopoulos; Ourania Anagnostopoulou; Petros P Sfikakis; Athol U Wells; George E Tzelepis
Journal:  Lung       Date:  2012-12-11       Impact factor: 2.584

7.  Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients.

Authors:  Esam H Alhamad; Majdy M Idrees; Mohammed O Alanezi; Ahmad A Alboukai; Shaffi Ahmad Shaik
Journal:  Ann Thorac Med       Date:  2010-04       Impact factor: 2.219

8.  Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis.

Authors:  Esam H Alhamad; Shaffi Ahmad Shaik; Majdy M Idrees; Mohammed O Alanezi; Arthur C Isnani
Journal:  BMC Pulm Med       Date:  2010-08-09       Impact factor: 3.317

Review 9.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

10.  Clinical characteristics and computed tomography findings in Arab patients diagnosed with pulmonary sarcoidosis.

Authors:  Esam H Alhamad; Mohammed O Alanezi; Majdy M Idrees; Mohammad K Chaudhry; Ali M AlShahrani; Arthur Isnani; Shaffi Shaikh
Journal:  Ann Saudi Med       Date:  2009 Nov-Dec       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.